Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Defining aging-associated factors that increase susceptibility to prostate cancer118
Survival following resection of 10,244 lung neuroendocrine tumours: a population study74
The diagnostic value of 68Ga-pentixafor PET/CT in differentiating adrenal aldosterone-producing adenomas from non-functional adenomas68
Metastatic neuroendocrine neoplasms of the breast: a systematic review60
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance57
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression46
Acknowledgement to reviewers41
Refining long-term surveillance requirements in patients with differentiated thyroid cancer35
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms34
Prognostic of recurrence and survival in poorly differentiated thyroid cancer32
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications31
Targeting growth hormone in cancer: future perspectives30
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas29
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs26
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing25
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study24
NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study24
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells23
FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications23
Update on the genetics of paragangliomas23
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells22
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation22
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet22
Impact of sex hormones on development and progression in NEN: a new therapeutic target?21
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts21
Peptide receptor radionuclide therapy in malignant insulinoma20
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas18
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells17
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation17
Metabolically active brown adipose tissue in PPGL: an observational cohort study17
B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer16
Determinants of false-positive plasma free metanephrines and methoxytyramine: the role of medications and chronic disease15
Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC15
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours15
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma15
PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)15
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia15
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells15
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction14
Whole-exome sequencing of rectal neuroendocrine tumors14
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen14
Gender-affirming care and endocrine-related cancers14
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring14
Protective TGFβ2/SMAD3 Axis Identified by TWAS in Papillary Thyroid Cancer13
Immunotherapy for endocrine tumours: a clinician’s perspective13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors13
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly13
Steroid profile in patients with breast cancer and in mice treated with mifepristone13
ThyroidPrint®: clinical utility for indeterminate thyroid cytology13
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective13
The role of the B7 family in autoimmune thyroid diseases and thyroid cancer13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms13
Artificial intelligence in pheochromocytoma and paraganglioma: from diagnostic modeling to clinically integrated decision support systems13
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study12
Clinical features of plurihormonal pituitary adenoma subtypes12
Single-Cell and Spatial Transcriptomics Define a Progenitor Subpopulation and Fibroinflammatory Niche at the Leading Edge of Parathyroid Carcinoma12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis12
Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA12
From bench to bedside in the sella: translational developments in pituitary tumour genetics12
Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma12
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR6012
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma12
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management11
Acknowledgement to reviewers11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma11
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer11
Acknowledgement to reviewers11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant11
Relationship between vascular density and microenvironment in medullary thyroid carcinoma11
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-210
Cancer in Ecuadorian subjects with Laron syndrome (ELS)10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland10
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC10
NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors10
Genetic disorders and insulinoma/glucagonoma10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity10
The role of stem cells in pituitary tumour formation10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice10
Systems biology successes and areas for opportunity in prostate cancer10
Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model9
Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas9
Beyond the three P’s: adrenal involvement in MEN19
Non-pituitary GH regulation of the tissue microenvironment9
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer9
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies9
Deiodinases in thyroid tumorigenesis9
Chemoembolization using streptozotocin versus embolization in metastatic NETs8
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center8
Surrogate molecular classification of LAR breast cancer in routine workflow8
In memoriam: Charis Eng MD PhD (1962–2024)8
Developing an epithelial signature for prognosis of papillary thyroid carcinoma8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer8
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma8
MicroRNAs as regulators of tumor metabolism8
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal8
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L28
The science behind the relations among cancer, height, growth patterns, and growth hormone axis8
Rethinking paraganglioma management: distinct clinical pathways for head and neck versus other sites8
Genotype-specific development of MEN 2 constituent components in 683 RET carriers8
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer8
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms8
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes8
0.48382115364075